Literature DB >> 21940575

Quantitative color mapping of the arterial enhancement fraction in patients with diffuse liver disease.

Sung Eun Kang1, Jeong Min Lee, Ernst Klotz, Kyung Won Kim, Jung Hoon Kim, Joon Koo Han, Byung Ihn Choi.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether color mapping of the arterial enhancement fraction of the liver with multiphasic liver CT can depict the hemodynamic changes associated with diffuse liver disease.
MATERIALS AND METHODS: A total of 142 patients (59 men, 83 women; mean age, 50 years) with diffuse liver disease and 25 patients acting as controls (11 men, 14 women; mean age, 54 years) were classified into three groups: controls (n = 25), patients with acute liver injury (no underlying chronic liver disease [n = 25], acute exacerbation of chronic liver disease [n = 17]), and patients with chronic hepatic injury (hepatitis [n = 25]; cirrhosis [n = 75], 25 each with Child-Pugh A, B, and C disease). The quantitative arterial enhancement fraction color map of the liver was generated from routine multiphasic CT images with prototype software. The mean arterial enhancement fractions of each group were compared by analysis of variance. The correlation between arterial enhancement fraction and Child-Pugh grade was evaluated with Spearman correlation. The area under the receiver operating characteristic curve for arterial enhancement fraction in the detection of acute liver injury and noncompensated chronic liver disease was calculated.
RESULTS: The mean arterial enhancement fractions of the liver in each group were significantly different (p < 0.0001, analysis of variance): control, 28.5%; acute liver injury without underlying chronic liver disease, 51.1%; acute exacerbation of chronic liver disease, 42.0%; chronic hepatitis, 25.4%; Child-Pugh A disease, 23.7%; Child-Pugh B disease, 32.2%; Child-Pugh C disease, 43.4%. Arterial enhancement fraction correlated with Child-Pugh grade (Spearman ρ = 0.553, p < 0.0001). The areas under the curve of arterial enhancement fraction in the detection of acute liver injury and noncompensated chronic liver disease were 0.96 and 0.78.
CONCLUSION: With color mapping of the arterial enhancement fraction derived from multiphasic liver CT scans, it is possible to visualize the hemodynamic changes associated with the severity of cirrhosis and acute liver injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940575     DOI: 10.2214/AJR.10.5943

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma.

Authors:  Jeong Min Lee; Jeong-Hee Yoon; Ijin Joo; Hyun Sik Woo
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

2.  Arterio-portal shunts in the cirrhotic liver: perfusion computed tomography for distinction of arterialized pseudolesions from hepatocellular carcinoma.

Authors:  Michael A Fischer; Herman P Marquez; Sonja Gordic; Bertil Leidner; Ernst Klotz; Peter Aspelin; Hatem Alkadhi; Torkel B Brismar
Journal:  Eur Radiol       Date:  2016-07-01       Impact factor: 5.315

Review 3.  Perfusion CT imaging of the liver: review of clinical applications.

Authors:  Hayri Oğul; Mecit Kantarcı; Berhan Genç; Berhan Pirimoğlu; Neşat Cullu; Yeşim Kızrak; Omer Yılmaz; Nevzat Karabulut
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

4.  Enhancement pattern mapping technique for improving contrast-to-noise ratios and detectability of hepatobiliary tumors on multiphase computed tomography.

Authors:  Peter C Park; Gye W Choi; Mohamed M Zaid; Dalia Elganainy; Danyal A Smani; John Tomich; Ray Samaniego; Jingfei Ma; Eric P Tamm; Sam Beddar; Eugene J Koay
Journal:  Med Phys       Date:  2019-11-19       Impact factor: 4.506

5.  Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.

Authors:  Bin Chai; Dongqiao Xiang; Wei Wang; Yanqiao Ren; Fuquan Wang; Jihua Wang; Guofeng Zhou; Chuansheng Zheng
Journal:  Cancer Imaging       Date:  2022-07-30       Impact factor: 5.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.